RSS-Feed abonnieren
DOI: 10.1055/s-2002-25154
Therapie der Anämie bei chronisch-entzündlichen Darmerkrankungen
Long-term Management of Anemia in Chronic Inflammatory Bowel DiseasePublikationsverlauf
25.5.2001
13.11.2001
Publikationsdatum:
17. April 2002 (online)

Zusammenfassung
Die Möglichkeiten in der antientzündlichen Stufentherapie, die Substitution von Mangelzuständen und auch die Behandlung von extraintestinalen Begleiterkrankungen bei chronisch- entzündlichen Darmerkrankungen erlauben dem Gastroenterologen eine individuell auf die Bedürfnisse seiner Patienten zugeschnittene Langzeitbetreuung.
Abstract
The development of a stepwise therapy, as detailed below, can be administered to the mostly young patients with Crohn’s disease and ulcerative colitis on an out-patient basis and appropriate to their needs. This is true not only for the activity of the disease, but also for extraintestinal manifestations. The numerous variations in the stepwise anti-inflammatory therapy of chronic inflammatory bowel disease, but also in the substitution therapy of deficiency states and the therapy of accompanying extraintestinal diseases provide the gastroenterologist with the possibility of a long-term treatment tailored to the needs of the individual patient.
Schlüsselwörter
Chronisch-entzündliche Darmerkrankungen - Extraintestinale Manifestationen - Anämie - Intravenöse Eisentherapie - Erythropoietin - Immunsuppressive Therapie
Key words
Inflammatory Bowel Disease - Anaemia - Intravenous Iron Therapy - Erythropoietin - Immunosuppressive Drugs
Literatur
- 1 Stange E F, Schreiber S, Raedler A. et al . Leitlinien der DGVS: Therapie chronisch-entzündlicher Darmerkrankungen. Ergebnisse einer Konsensuskonferenz der Deutschen Gesellschaft für Verdauungs- und Stoffwechselkrankheiten. Z Gastroenterologie. 1997; 35 541-554
- 2 Stange E F, Riemann J, von Herbay A, Lochs H. et al . Diagnostik und Therapie der Colitis ulcerosa: Ergebnisse einer evidenzbasierten Konsensuskonferenz der DGVS. Z Gastroenterologie. 2001; 39 19-72
- 3 May B. Extraintestinale Manifestationen der chronisch entzündlichen Darmerkrankungen. Leber Magen Darm. 1997; 29 (Suppl. 3) 17-20
- 4 Gaschè C, Dejaco C, Reinisch W. et al . Sequential Treatment of Anemia in Ulcerative Colitis with Intravenous Iron and Erythropoietin. Digestion. 1999; 60 262-267
- 5 Gaschè C, Reinisch W, Lochs H. et al . Anemia in Crohn‘s Disease - Importance of Inadequate Erythropoietin Production and Iron Deficiency. Digestive Diseases and Sciences. 1994; 39 (Nr. 9) 1930-1934
- 6 Gaschè C, Waldhoer T, Feichtenschlager T. et al . Prediction of Response to Iron Sucrose in Inflammatory Bowel Disease-Associated Anemia. Am Journal of Gastroenterology. 2001; 96 (No. 8) 2382-2387
- 7 Gaschè C. Anemia in IBD: The overlooked Villain. Inflammatory bowel disease. 2000; 6 142-150
- 8 Mickisch O, Lutz-Vorderbrügge A, Küppers B. Neue Aspekte in der ambulanten Langzeittherapie chronisch-entzündlicher Darmerkrankungen. Verdauungskrankheiten. 2000; 18 (Nr. 1) 25-32
- 9 Bartels U, Strandberg Pedersen N, Jarnum S. Iron absorption and serum ferritin in chronic inflammatory bowel disease. Scand J Gastroenterol. 1978; 13 649-656
- 10 Kaplinsky N, Frank O. Salicylazosulphapyridine-induced Heinz Body anemia. Acta Haematol. 1978; 59 310-314
- 11 Yates P, Macht M, Williams N A, Elson C J. Red cell autoantibody production by colonic mononuclear cells from a patient with ulcerative colitis and autoimmune haemolytic anemia. Br J Haematol. 1992; 82 753-756
- 12 Jelkmann W, Pagel H, Wolff M, Fandrey J. Monokines inhibiting erythropoietin production in human hepatoma cultures and in isolated perfused rat kidneys. Life Sci. 1992; 50 301-308
- 13 Jelkmann W, Fandrey J, Frede S, Pagel H. Inhibition of erythropoietin production by cytokines - Implications for the anemia involved in inflammatory states. Ann NY Acad Sci. 1994; 718 300-309
- 14 Küppers B, Mickisch O, Lutz-Vorderbrügge A. Erste Erfahrungen mit der ambulanten Erythropoietin-Behandlung eisenrefraktärer Anämien bei chronisch-entzündlichen Darmerkrankungen. Verdauungskrankheiten. 1999; 17 (Nr. 1) 21-30
- 15 Schreiber S, Howaldt S, Schnoer M. et al . Recombinant erythropoietin for the treatment of anemia in inflammatory bowel disease. N Engl J Med. 1996; 334 619-624
- 16 Cartwright G E. The anemia of chronic disorders. Semin Haematol. 1966; 3 351-375
- 17 Means R T. Advances in the anemia of chronic disease. Int J Haematol. 1999; 70 7-12
- 18 Schreiber S, Wedel S. Diagnosis and Treatment of anemia in inflammatory bowel disease. Inflammatory bowel disease. 1997; 3 206-216
- 19 Gaschè C, Dejaco C, Waldhoer T. et al . Intravenous Iron and Erythropoietin for Anemia Associated with Crohn‘s Disease. Ann Intern Med. 1997; 126 782-787
- 20 Beglinger C, Hess B, Ruchti C. Severe chronic iron deficiency in a 17- year-old student. Schweiz Rundsch Med Prax. 1998; 87 622-626 (18)
- 21 Rath H C, Caesar I, Roth M, Schölmerich J. Nutritional deficiencies and complications in chronic inflammatory bowel diseases. Med Klin. 1998; 93 6-10 (1)
- 22 Thomas L. Labor und Diagnose. Marburg; Medizinische Verlagsgesellschaft 1992: 397-407, 649-653
- 23 Danielson B G, Geisser P, Schneider W. Iron Therapy - with Special Emphasis on Intravenous Administration. Vifor (International) Inc. 1996; 51-60
- 24 Geisser P, Baer M, Schaub E. Structure/Histotoxicity Relationship of Parenteral Iron Preparations. Arzneim-Forsch/Drug Res. 1992; 43 1439-1452 (II) 1)
- 25 Cullen P, Söffker J, Höpfl M. et al . Hypochromic red cells and reticulocyte haemglobin content as markers of iron-deficient erythropoiesis in patients undergoing chronic haemodialysis. Nephrol Dial Transplant. 1999; 14 659-665
- 26 Schaefer R M, Schaefer L. Hypochromic red blood cells and reticulocytes. Kidney International. 1999; 55 (Suppl. 69) 44-48
- 27 Hörl W H, Kaltwasser J P, Schäfer R M, Asmus G. Eisen- und rhEPO-Therapie bei Niereninsuffizienz - Stand 1997. J Pediatr. 1996; 129 258-263
- 28 Schaefer R M. Optimierte Eisengabe bei der chronischen Anämie. Satellitensymposium Erythropoetin Beyond Nephrology Wiesbaden; 11. April 1999
- 29 Heinrich H C. Eisenabsorption oraler FE(II). bzw. FE(III)-Präparate. Deutsche Apotheker-Zeitschrift. 1996; 14 681-690
- 30 Burns D L, Mascioli E A, Bistrian B R. Parenteral iron dextran therapy: A review. Nutrition. 1995; 11 163-168
- 31 Höchli P, Wagenhäuser F J, Fehr J. Repeated continuous administration of low doses of intravenous iron in anemic patients with active rheumatoid arthritis. (Letters to the Editor). Eur J Haematol. 1993; 51 54-55
- 32 Martini A, Ravelli A, Di Fuccia G. et al . Intravenous iron therapy for severe anaemia in systemic-onset juvenile chronic arthritis. Lancet. 1994; 344 1052-1054
- 33 Babbs C F. Oxygen radicals in ulcerative colitis. Free Radic Biol Med. 1992; 13 169-181 (2)
- 34 Biemond P, Swaak A J, v. Eijk H G, Koster J F. Superoxide dependent iron release from ferritin in inflammatory diseases. Free Radic Biol Med. 1988; 4 (3) 185-198
- 35 Grisham M B, Granger D N. Neutrophil-mediated mucosal injury. Role of reactive oxygen metabolites. Dig Dis Sci. 1988; 33 (3 Suppl.) 6S-15S
- 36 Muntane J, Puig-Parellada P, Mitjavila M T. Iron metabolism and oxidative stress during acute and chronic phases of experimental inflammation: effect of iron-dextran and deferoxamine. J Lab Clin Med. 1995; 126 435-443 (5)
- 37 Zanen A L, Adriaansen H J, van Bommel E F, Posthuma R, de Jong GM Th. Oversaturation of transferrin after intravenous ferric gluconate (Ferrlecit) in haemodialysis patients. Nephrol Dial Transplant. 1996; 11 820-824
- 38 Weiss G. Iron and anemia of chronic disease. Kidney International. 1999; 55 (Suppl. 69) 12-17
- 39 Patruta S, Hörl W H. Iron and infection. Kidney International. 1999; 55 (Suppl. 69) 125-130
- 40 Macdougall I C. Strategies for iron supplementation: oral versus intravenous. Kidney Int. 1999; Suppl. 69 61-66
- 41 Koury M J. Investigating erythropoietin resistance. N Engl J Med. 1993; 328 205-206
- 42 Ludwig H. et al . Recombinant human erythropoietin for the correction of cancer-associated anemia with and without concomitant cytotoxic chemotherapy. Cancer. 1995; 76 2319-2329
- 43 Means R T, Krantz S B. Inhibition of human erythroid colony-forming units by gamma interferon can be corrected by recombinant human erythropoietin. Blood. 1991; 78 2564-2567
Dr. med. O. Mickisch
Gastroenterologische Schwerpunktpraxis, Drs. B. Küppers/O.
Mickisch/W. Baniewicz, Gastroenterologie/Innere Medizin
O 7, Nr. 14 (Am Wasserturm)
68161 Mannheim